Wed, Apr 16, 2014, 5:59 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Star Scientific, Inc. (CIGX) Message Board

thetimehascomethewalrussaid 6 posts  |  Last Activity: Mar 12, 2014 2:17 PM Member since: Mar 1, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Star Scientific added to Dr Mullan bio

    by repo_man_one Mar 12, 2014 1:10 PM
    thetimehascomethewalrussaid thetimehascomethewalrussaid Mar 12, 2014 2:17 PM Flag

    "That is why the shorts are so worried imho"

    What the shorts are worried about WHY Mullan joined Star. With a great job, high peer recognition, a great reputation to ,protect, there is no way he ties his star to STSI (Rock Creek Pharmaceuticals) UNLESS he saw something really big, really dramatic and really SURE - a "LOCK." Remember, for guys like Mullan, REPUTATION IS EVERYTHING. You don't join a Star with all its baggage, UNLESS YOU ARE SURE IT'S GOING TO WORK OUT.

    SO here's a guy with a CV a mile long, degrees all over the place, a huge reputation and a keen intellect, and a FULL UNDERSTANDING of the science and he says, "THIS IS MY FUTURE"

    So if you know more about the science than Mullan, and you have as many degrees and have spent years working on anata*** and you don't like Star - SELL. If not, why not JOIN THE GENIUS and make a ton of money?.

  • thetimehascomethewalrussaid thetimehascomethewalrussaid Feb 24, 2014 12:56 PM Flag

    • “Stupid pumpers think STSI is a buyout target by big Pharma. It is not.
    Anyone can manufacture Anatabine. It is naturally occurring. And don't tell me that STSI's patent have some huge value. Because they don't.”



    Good point, Star’s anatabine patents are proaly worthless. I think someone should call the award winning physician, scientists/researcher Dr. Michael Mullan, MD, PHD and tell him.

    And could someone else call the extremely successful Dr. Christopher Chapman, MD, wgi has taken pharmaceuticals through the FDA to market and een involved with several mutli billion dollar companies that he’s wasting his time.

    Oh, yes, and then there’s Ted Jenkins who just left his very successful career at Oppenheimer to join Star, full time. He should have taken a good long look at Star before going “all in.”

    And then there’s Goldman Capital Management, BlacRock (who just went over 5%), Trade Winds, Vanguard, State Street, etc, probably none of whom know what a ad investment they have been holding or adding to.

  • thetimehascomethewalrussaid by thetimehascomethewalrussaid Feb 19, 2014 3:14 PM Flag

    Ok, I spelt it wrong to get your attention, it’s the “pair of Docs” who are now running Star who are making the difference. They are:

    Dr. Michael Mullan, CEO, initially trained as a physician he also earned a PhD from London University, studying the molecular genetics of familial Alzheimer’s Disease. Dr. Mullan has been an Alzheimer’s Disease researcher for over 25 years and has published over 200 peer review scientific papers on Alzheimer’s Disease and related disorders. He has been President and CEO of the internationally-known Roskamp Institute, the non-profit biomedical research facility which specializes in Alzheimer’s Disease research. With his colleagues at the Roskamp Institute he has pioneered new medical treatments to improve memory in Alzheimer’s Disease. These treatments are in the advanced stage of clinical testing worldwide. Dr Mullan and colleagues from the Roskamp Institute this past fall received an award from The Society for Neurology for reversing brain damage in mice. The study was funded by the US Department of Defense.

    Christopher Chapman, MD, President. He served as Senior Director of Medical Affairs with Quintiles/BRI ($8 billion company) the largest contract research organization in the U.S., from 1995 until 2000. In that capacity, Dr. Chapman had oversight responsibility for the support of new drug applications, clinical studies, and device submissions to the FDA for approval. From 1992 until 1994, Dr. Chapman was Medical Director at Regeneron Pharmaceuticals ($33 billion company – from $12 a share to $333 a share in the past 5 years)). Dr. Chapman is a graduate of the Georgetown University School of Medicine.

    The above is a watered-down version of their CV’s. Here is what you NEED TO KNOW about them:
    They are now the two top officers at Star (Rock Creek)
    They know the science as well as anyone with the possible exception of Paul Ladenson, MD, at Johns Hopkins.
    They are “all-in” on Star and its science.
    They will be speaking to Star s

  • thetimehascomethewalrussaid by thetimehascomethewalrussaid Feb 18, 2014 3:39 PM Flag

    Ok, I spelt it wrong to get your attention, it’s the “pair of Docs” who are now running Star who are making the difference. They are:

    Dr. Michael Mullan, CEO, a physician he also earned a PhD from London University, studying the molecular genetics of familial Alzheimer’s Disease. Dr. Mullan has been an Alzheimer’s Disease researcher for over 25 years and has published over 200 peer review scientific papers on Alzheimer’s and related disorders. He has been President and CEO of the internationally-known Roskamp Institute, the non-profit biomedical research facility which specializes in Alzheimer’s. With his colleagues at the Roskamp Institute he has pioneered new medical treatments to improve memory in Alzheimer’s Disease. These treatments are in the advanced stage of clinical testing worldwide. Dr Mullan and colleagues from the Roskamp, this past fall received an award from The Society for Neurology for reversing brain damage in mice. The study was funded by the US Department of Defense.

    Christopher Chapman, MD, President. He served as Senior Director of Medical Affairs with Quintiles/BRI ($8 billion) the largest contract research organization in the U.S., from 1995 until 2000. In that capacity, Dr. Chapman had oversight responsibility for the support of new drug applications, clinical studies, and device submissions to the FDA for approval. From 1992 until 1994, Dr. Chapman was Medical Director at Regeneron Pharmaceuticals ($33 billion). Dr. Chapman is a graduate of the Georgetown University School of Medicine.

    * The above is a watered-down version of their CV’s. Here is what you NEED TO KNOW about them:
    * They are now the two top officers at Star (Rock Creek)
    * They know the science as well as anyone with the possible exception of Paul Ladenson, MD, at Johns Hopkins.
    * They are “all-in” on Star and its science.
    * They will be speaking to Star shareholders and the world on March 20th, in Sarasota.

  • thetimehascomethewalrussaid by thetimehascomethewalrussaid Feb 7, 2014 10:26 AM Flag

    They don’t scare anymore. The weak hands have sold – maybe to return, maybe not. Those who are left have seen every underhanded short trick in the book, from the “former Louisiana prosecutor, to the dippy little posters on here, to the Feuerstein pap, to the “nation wide” law firm. They’ve seen it all, and they aren’t invested in Star (Rock Creek Pharmaceuticals) for short term manipulation, they’re in it for the SCIENCE.
    When you blow away all the smoke, here’s what they see. They see Dr. Mullan with a CV that reads like a Nobel Laureate, they see Dr. Christopher Chapman as a rare combination of successful medical/research professional and a really successful BUSINESSMAN (and WE have him) - both of these gentlemen – in spite of all the negative stuff – have tied their futures to Rock Creek and its science. I ask this one question: “Who knows it better?”

    They see the founder putting up another $22 million. They see Trade Winds and Goldman Capital holding strong and they see Black Rock double up on their investment (since all the bad news was out) requiring a higher level of filing (over 5%).

    So a few pithy comments from some shorts’ dippy little friends just doesn’t make it anymore. The longs are waiting for the science to find its proper place in the world, and everything else is a distraction.

  • thetimehascomethewalrussaid by thetimehascomethewalrussaid Feb 6, 2014 9:52 AM Flag

    Talk about a perfect storm, this winter has seem one storm after another with large accumulations of ice and snow, followed by freezing temperatures all the way down to the Gulf of Mexico This difficult winter has put an unusual strain on the glycol business. Is the antifreeze product that airlines use to de-ice planes preparing for take off. The unusually blistery weather means more de-icing, and weather delays mean that many planes ate de-iced several times while waiting for departure.

    Along comes GlyEco. This is the company that “buys” used glycol (usually its free, some will even pay the company to remove it), the re-cycle it and sell it as new. So how does this winter affect GlyEco? Well, all the snow and ice storms are having three favorable effects: A) the extreme weather is causing glycol shortages, driving up the price. B) the high use of Glycol has provided record supplies of “used” glycol available for the ONLY recycler of the product, and C) Demand is rising for additional supplied of glycol.
    For GlyEco – it looks like a “Perfect Storm!”

STSI
0.7394-0.0413(-5.29%)Apr 16 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.